The FDA is weighing the regulatory fate of KarXT — an oral dual M1/M4 muscarinic acetylcholine receptor (mAChR) agonist — for schizophrenia. If approved, the fixed-dose combination of xanomeline and ...
COBENFY represents the first new pharmacological approach to treat schizophrenia in decades, with a mechanism of action distinct from current therapies PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers ...
Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback